Stockscreener 앱 받기
2.99
4.78%
-0.15
전일 마감가:
$3.14
열려 있는:
$3.14
하루 거래량:
2.75M
Relative Volume:
1.05
시가총액:
$257.77M
수익:
$7.62M
순이익/손실:
$-271.60M
주가수익비율:
-0.8538
EPS:
-3.5018
순현금흐름:
$-271.54M
1주 성능:
-12.06%
1개월 성능:
-13.33%
6개월 성능:
-79.81%
1년 성능:
-74.11%
1일 변동 폭
$2.9512
$3.15
1주일 범위
$2.93
$3.4299
52주 변동 폭
$2.93
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
명칭
Eyepoint Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
2.99 | 257.77M | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-02 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2026-08-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2026-08-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2026-08-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-08-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2026-07-16 | 개시 | Stifel | Buy |
| 2026-07-08 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-06-17 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Inc 주식(EYPT)의 최신 뉴스
Here's Why You Should Add EYPT Stock to Your Portfolio Now - Zacks Investment Research
Five parties report an EyePoint (EYPT) stake but disclaim ownership of shares held by Managed Funds. - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - GlobeNewswire Inc.
PV3B Stock Price and Chart — HAN:PV3B - TradingView
PV3B Stock Price and Chart — HAN:PV3B - TradingView
EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - kalkine.ca
EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - kalkine.com.au
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against EyePoint, Inc. (EYPT) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT) - The Globe and Mail
EYPT Investigation Alert: EyePoint, Inc. Investors Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
EyePoint at Cantor conference: mixed trial data leaves key catalyst ahead - Investing.com Canada
EyePoint at Cantor conference: mixed trial data leaves key catalyst ahead - Investing.com India
EyePoint posts updated presentation showing LUGANO Phase 3 DURAVYU topline results, NDA path to H1 2027 - TradingView
Eye drug cuts injections 42% in EyePoint (EYPT) trial but misses its main goal - Stock Titan
EyePoint Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Transcript : EyePoint, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
EyePoint at Citi summit: wet AMD setback, but path stays open - Investing.com India
EyePoint at Citi summit: wet AMD setback, but path stays open - Investing.com Nigeria
EyePoint at Citi summit: wet AMD setback, but path stays open - Investing.com UK
EyePoint at Citi summit: wet AMD setback, but path stays open By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - GlobeNewswire Inc.
INVESTIGATION ALERT: Investigation Launched Into EyePoint, Inc. (EYPT), Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - Barchart.com
Investment firm discloses double-digit stake in EyePoint (EYPT) - Stock Titan
EyePoint's stock plunges 66% after failed Phase 3 trial for wet AMD treatment. - Pluang
Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - PR Newswire
EYPT News | EYEPOINT INC (NASDAQ:EYPT) - ChartMill
EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm - GlobeNewswire Inc.
EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO - finance.yahoo.com
EyePoint faces securities fraud probe after tri... - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - PR Newswire
EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals - GlobeNewswire
EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
EyePoint stock drops as TD Cowen downgrades (EYPT:NASDAQ) - Seeking Alpha
TD Cowen Downgrades EyePoint Pharmaceuticals to Hold From Buy, Adjusts PT to $4 From $20 - marketscreener.com
EyePoint Announces Upcoming Investor Conference and Retina Society Presentations - quiverquant.com
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting - marketscreener.com
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting - GlobeNewswire
TD Cowen downgrades EyePoint stock to Hold on trial concerns By Investing.com - Investing.com Canada
TD Cowen downgrades EyePoint stock to Hold on trial concerns - investing.com
TD Cowen downgrades EyePoint stock to Hold on trial concerns By Investing.com - Investing.com UK
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm - Sahm
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law - financialcontent.com
Eyepoint Pharmaceuticals Inc (EYPT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law - Business Wire
Eyepoint Pharmaceuticals Inc (EYPT) Peer Comparison – Compare with Others - Value Research
EyePoint After LUGANO: Primary Endpoint Miss, Asymmetric Risk-Reward (NASDAQ:EYPT) - Seeking Alpha
Eyepoint Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Eyepoint Inc 주식 (EYPT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lurker Nancy | Officer |
Jul 21 '26 |
Proposed Sale |
13.05 |
421,235 |
5,497,117 |
0 |
| Duker Jay S. | President and CEO |
Jul 10 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
17,653 |
| Ribeiro Ramiro | Chief Medical Officer |
Jun 30 '26 |
Option Exercise |
8.26 |
4,875 |
40,268 |
4,875 |
| Ribeiro Ramiro | Chief Medical Officer |
Jun 30 '26 |
Sale |
15.01 |
4,875 |
73,167 |
0 |
| Elston George | Chief Financial Officer |
May 25 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
95,318 |
| Ribeiro Ramiro | Chief Medical Officer |
Apr 17 '26 |
Option Exercise |
8.26 |
2,437 |
20,130 |
2,437 |
| Ribeiro Ramiro | Chief Medical Officer |
Apr 17 '26 |
Sale |
15.00 |
2,437 |
36,555 |
0 |
| Ramiro Ribeiro | Officer |
Apr 17 '26 |
Proposed Sale |
14.81 |
9,750 |
144,398 |
0 |
| Duker Jay S. | President and CEO |
Mar 16 '26 |
Buy |
13.15 |
1,500 |
19,724 |
100,665 |
| Ribeiro Ramiro | Chief Medical Officer |
Mar 04 '26 |
Option Exercise |
8.26 |
2,438 |
20,138 |
2,438 |
4.22%
자본화:
|
볼륨(24시간):